



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic



Mouse Anti- CD19 Monoclonal Antibody

CLX29AP	CLX29PE
CLX29B	CLX29PCP
CLX29F	CLX29APC

Clone: LT19

Isotype: Mouse IgG1

Specificity:

The antibody LT19 reacts with CD19 (B4), a 95 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on B lymphocytes and follicular dendritic cells; it is lost on plasma cells. HLDA 10

Immunogen: Daudi human Burkitt lymphoma cell line.

Species Reactivity: Human.

Application: Flow Cytometry and Immunoprecipitation.

Conjugate Preparation:

The purified antibody is conjugated with Biotin-LC-NHS, Fluorescein isothiocyanate (FITC), R-Phycoerythrin (PE), Peridinin-chlorophyll-protein complex (PerCP) or cross-linked Allophycocyanin (APC) under optimum conditions. The conjugates are purified by size-exclusion chromatography and adjusted for direct use (FITC, PE, APC, PerCP). No reconstitution is necessary.

Presentation:

Purified: 0.1 mg (1 mg/mL) purified IgG buffered in PBS with 15 mM sodium azide, approx. pH 7.4. (Purified by protein-A affinity chromatography; purity > 95% by SDS-PAGE).

Biotin: 0.1 mg (1 mg/mL) of Biotin conjugated IgG buffered in tris buffered saline (TBS) with 15 mM sodium azide, approx. pH 8.0.

FITC: 2 mL of FITC conjugated IgG buffered in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide. Sufficient for 100 tests.

PE: 2 mL of PE conjugated IgG buffered in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide. Sufficient for 100 tests.

PerCP: 1 mL of APC conjugated IgG buffered in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide. Sufficient for 100 tests.

APC: 1 mL of APC conjugated IgG buffered in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide. Sufficient for 100 tests.

Storage / Stability:

Store in the dark at 2-8°C. Do not freeze all formats. Avoid prolonged exposure to light of conjugates. Do not use after expiration date stamped on vial label.

Continued Overleaf.....

Visit our website for your local distributor.

CEDARLANE®

www.cedarlanelabs.com

An ISO 9001:2000 and ISO 13485:2003
registered company.

In CANADA: Toll Free: 1-800-268-5058

4410 Paletta Court, Burlington, ON L7L 5R2 ph: (289) 288-0001, fax: (289) 288-0020
e-mail: general@cedarlanelabs.com

In the USA: Toll Free: 1-800-721-1644

1210 Turrentine Street, Burlington, NC 27215 ph: (336) 513-5135, fax: (336) 513-5138
e-mail: service@cedarlanelabs.com

Usage:

Recommended dilutions for Flow Cytometry analysis of human blood cells:

Purified: 5 µg/ml

Biotin: 1:200 dilution

FITC: 20 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension.

PE: 20 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension.

PerCP: 10 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension.

APC: 10 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension.

***Optimal working concentrations should be determined by the investigator.**

Background:

CD19 is a transmembrane glycoprotein of Ig superfamily expressed by B cells from the time of heavy chain rearrangement until plasma cell differentiation. It forms a tetrameric complex with CD21 (complement receptor type 2), CD81 (TAPA-1) and Leu13. Together with BCR (B cell antigen receptor), these complex signals to decrease B cell threshold for activation by the antigen. Besides being signal-amplifying coreceptor for BCR, CD19 can also signal independently of BCR coligation and it turns out to be a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.

References:

- *Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. *J Immunol.* 1999 Jun 15;162(12):7088-94.
- *Inabe K, Kurosaki T: Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. *Blood.* 2002 Jan 15;99(2):584-9.
- *van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody-deficiency syndrome due to mutations in the CD19 gene. *N Engl J Med.* 2006 May 4;354(18):1901-12.
- *Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis. *Arthritis Rheum.* 2007 Sep;56(9):3057-69.
- *Elias F, Flo J, Lopez RA, Zorzopoulos J, Montaner A, Rodriguez JM: Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. *J Immunol.* 2003 Oct 1;171(7):3697-704.
- *Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. *Blood.* 2005 Nov 15;106(10):3567-74. Epub 2005 Jul 26.
- *Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M: Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. *Int J Lab Hematol.* 2013 Sep 13. doi: 10.1111/ijlh.12149. *Kayserova J, Vcelakova J, Stechova K, Dudkova E, Hromadkova H, Sunnik Z, Kolouskova S, Spisek R, Sediva A: Decreased dendritic cell numbers but increased TLR9-mediated interferon-alpha production in first degree relatives of type 1 diabetes patients. *Clin Immunol.* 2014 Jul;153(1):49-55.

Laboratory Reagent For Research Use Only

JK 11/12/18